{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:28:59Z","timestamp":1794018539717,"version":"4.8.0"},"reference-count":88,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,4,27]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The treatment of multiple myeloma is considered a continuously evolving paradigm as a result of the growing availability of new and highly effective drugs, including first- and second-generation proteasome inhibitors, immunomodulatory agents, and monoclonal antibodies. Clinical trials advocate long-term rather than short-term treatment schedules with combinations of these new anti\u2013myeloma drug classes. Although the overall toxicity profile of the recommended regimens can be considered favorable, their increasing complexity and prolonged use warrant a heightened vigilance for early and late side effects, a priori because real-life patients can be more frail or present with 1 or more comorbidities. The treatment decision process, at diagnosis and at relapse, therefore requires myeloma physicians to carefully balance efficacy and toxicity profiles for each individual patient. Early and\/or unnecessary tapering or treatment discontinuation for drug-related adverse events may not only reduce patients\u2019 quality of life, but also negatively impact their outcome. Accurate knowledge in recognizing and managing the potential side effects of present-day treatment regimens is therefore a cornerstone in myeloma care. Using 5 case vignettes, we discuss how to prevent and manage the most common nonhematological adverse events of anti\u2013myeloma treatment regimens containing proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies.<\/jats:p>","DOI":"10.1182\/blood-2017-01-725705","type":"journal-article","created":{"date-parts":[[2017,3,9]],"date-time":"2017-03-09T02:10:45Z","timestamp":1489025445000},"page":"2359-2367","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":53,"title":["How I manage the toxicities of myeloma drugs"],"prefix":"10.1182","volume":"129","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0147-2291","authenticated-orcid":false,"given":"Michel","family":"Delforge","sequence":"first","affiliation":[{"name":"Department of Hematology, University Hospital Leuven, Leuven, Belgium; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3302-8726","authenticated-orcid":false,"given":"Heinz","family":"Ludwig","sequence":"additional","affiliation":[{"name":"Wilhelminen Cancer Research Institute, First Department of Medicine, Center for Oncology, Haematology and Palliative Care, Wilhelminenspital, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111903331569600_B1","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 10.1001\/jamaoncol.2016.5688 [published online ahead of print December 3, 2016]","author":"Global Burden of Disease Cancer Collaboration"},{"issue":"12","key":"2019111903331569600_B2","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"24","key":"2019111903331569600_B3","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111903331569600_B4","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111903331569600_B5","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol"},{"issue":"2","key":"2019111903331569600_B6","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111903331569600_B7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol"},{"issue":"17","key":"2019111903331569600_B8","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"2019111903331569600_B9","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J Clin Oncol"},{"issue":"9594","key":"2019111903331569600_B10","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","article-title":"Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial","volume":"370","author":"Facon","year":"2007","journal-title":"Lancet"},{"issue":"1","key":"2019111903331569600_B11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"issue":"21","key":"2019111903331569600_B12","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"issue":"21","key":"2019111903331569600_B13","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111903331569600_B14","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"San Miguel","year":"2013","journal-title":"Lancet Oncol"},{"issue":"1","key":"2019111903331569600_B15","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2016-03-705210","article-title":"Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma","volume":"128","author":"Usmani","year":"2016","journal-title":"Blood"},{"issue":"14","key":"2019111903331569600_B16","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"2019111903331569600_B17","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111903331569600_B18","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N Engl J Med"},{"issue":"20","key":"2019111903331569600_B19","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1182\/blood-2014-07-552059","article-title":"Curing myeloma at last: defining criteria and providing the evidence","volume":"124","author":"Barlogie","year":"2014","journal-title":"Blood"},{"issue":"5","key":"2019111903331569600_B20","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/ejh.12790","article-title":"Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis","volume":"97","author":"Ramsenthaler","year":"2016","journal-title":"Eur J Haematol"},{"issue":"26","key":"2019111903331569600_B21","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2012.48.4626","article-title":"Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials","volume":"31","author":"Sonneveld","year":"2013","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111903331569600_B22","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/leu.2009.26","article-title":"Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial","volume":"23","author":"Reeder","year":"2009","journal-title":"Leukemia"},{"issue":"21","key":"2019111903331569600_B23","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2016-01-693580","article-title":"VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial","volume":"127","author":"Moreau","year":"2016","journal-title":"Blood"},{"issue":"9758","key":"2019111903331569600_B24","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","article-title":"Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study","volume":"376","author":"Cavo","year":"2010","journal-title":"Lancet"},{"issue":"5","key":"2019111903331569600_B25","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"issue":"6","key":"2019111903331569600_B26","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.3324\/haematol.2013.099341","article-title":"Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy","volume":"99","author":"Mateos","year":"2014","journal-title":"Haematologica"},{"issue":"11","key":"2019111903331569600_B27","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S1470-2045(10)70068-1","article-title":"Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues","volume":"11","author":"Delforge","year":"2010","journal-title":"Lancet Oncol"},{"issue":"4","key":"2019111903331569600_B28","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/leu.2011.346","article-title":"Management of treatment-emergent peripheral neuropathy in multiple myeloma","volume":"26","author":"Richardson","year":"2012","journal-title":"Leukemia"},{"issue":"2","key":"2019111903331569600_B29","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s11060-014-1632-x","article-title":"Chemotherapy-induced peripheral neuropathies in hematological malignancies","volume":"121","author":"Jongen","year":"2015","journal-title":"J Neurooncol"},{"issue":"8","key":"2019111903331569600_B30","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1038\/leu.2015.80","article-title":"Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma","volume":"29","author":"Mai","year":"2015","journal-title":"Leukemia"},{"issue":"11","key":"2019111903331569600_B31","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S1470-2045(10)70206-0","article-title":"Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65\/GMMG-HD4 trial","volume":"11","author":"Broyl","year":"2010","journal-title":"Lancet Oncol"},{"issue":"12","key":"2019111903331569600_B32","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/ajh.23835","article-title":"Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study","volume":"89","author":"Tacchetti","year":"2014","journal-title":"Am J Hematol"},{"issue":"1","key":"2019111903331569600_B33","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1600-0609.2010.01533.x","article-title":"Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study","volume":"86","author":"Dimopoulos","year":"2011","journal-title":"Eur J Haematol"},{"issue":"6","key":"2019111903331569600_B34","first-page":"741","article-title":"Psychometric evaluation of the functional assessment of cancer therapy\/gynecologic oncology group-neurotoxicity (Fact\/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy","volume":"13","author":"Calhoun","year":"2003","journal-title":"Int J Gynecol Cancer"},{"key":"2019111903331569600_B35","unstructured":"Common Terminology Criteria for Adverse Events. (CTCAE version 4.0). https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed December 10, 2016."},{"issue":"12","key":"2019111903331569600_B36","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.jpain.2015.07.009","article-title":"Inhaled cannabis for chronic neuropathic pain: a meta-analysis of individual patient data","volume":"16","author":"Andreae","year":"2015","journal-title":"J Pain"},{"issue":"9","key":"2019111903331569600_B37","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1038\/leu.2009.83","article-title":"Ascorbic acid inhibits antitumor activity of bortezomib in vivo","volume":"23","author":"Perrone","year":"2009","journal-title":"Leukemia"},{"issue":"3","key":"2019111903331569600_B38","first-page":"194","article-title":"Management of thalidomide toxicity","volume":"1","author":"Ghobrial","year":"2003","journal-title":"J Support Oncol"},{"issue":"7","key":"2019111903331569600_B39","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1016\/j.clml.2016.04.013","article-title":"Treatment with doxycycline for severe bortezomib-associated blepharitis","volume":"16","author":"Veys","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"24","key":"2019111903331569600_B40","doi-asserted-by":"crossref","first-page":"5661","DOI":"10.1182\/blood-2012-03-414359","article-title":"An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and\/or refractory multiple myeloma","volume":"119","author":"Vij","year":"2012","journal-title":"Blood"},{"key":"2019111903331569600_B41","doi-asserted-by":"crossref","first-page":"e384","DOI":"10.1038\/bcj.2015.112","article-title":"Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?","volume":"6","author":"Rosenthal","year":"2016","journal-title":"Blood Cancer J"},{"key":"2019111903331569600_B42","article-title":"Molecular mechanisms of the cardiotoxicity of the proteasomal-targeted drugs bortezomib and carfilzomib. Cardiovasc Toxicol. 2016. [published online ahead of print July 7, 2016]","author":"Hasinoff"},{"issue":"10","key":"2019111903331569600_B43","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1007\/s00277-014-2026-z","article-title":"Bortezomib-induced acute congestive heart failure: a case report and review of literature","volume":"93","author":"Subedi","year":"2014","journal-title":"Ann Hematol"},{"issue":"20","key":"2019111903331569600_B44","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1182\/blood-2016-05-717769","article-title":"Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib","volume":"128","author":"Kumar","year":"2016","journal-title":"Blood"},{"issue":"22","key":"2019111903331569600_B45","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.4794.4794","article-title":"Evaluation of cardiovascular comorbidities among patients with multiple myeloma in the United States [abstract]","volume":"128","author":"Lenihan","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2019111903331569600_B46","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/ejh.12677","article-title":"\u2018Real-life\u2019 experience of preapproval carfilzomib-based therapy in myeloma - analysis of cardiac toxicity and predisposing factors","volume":"97","author":"Danhof","year":"2016","journal-title":"Eur J Haematol"},{"issue":"23","key":"2019111903331569600_B47","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.4250.4250","article-title":"Serial echocardiographic assessment of patients (Pts) with relapsed multiple myeloma (RMM) receiving carfilzomib and dexamethasone (Kd) vs bortezomib and dexamethasone (Vd): a substudy of the phase 3 Endeavor Trial (NCT01568866) [abstract]","volume":"126","author":"Russell","year":"2015","journal-title":"Blood"},{"issue":"5","key":"2019111903331569600_B48","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.clml.2016.01.008","article-title":"Management of carfilzomib-associated cardiac adverse events","volume":"16","author":"Mikhael","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"2019111903331569600_B49","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N Engl J Med"},{"issue":"8","key":"2019111903331569600_B50","doi-asserted-by":"crossref","first-page":"E116","DOI":"10.1002\/ajh.23733","article-title":"Clarithromycin overcomes resistance to lenalidomide and dexamethasone in multiple myeloma","volume":"89","author":"Ghosh","year":"2014","journal-title":"Am J Hematol"},{"issue":"1","key":"2019111903331569600_B51","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2014.107714","article-title":"Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients","volume":"100","author":"Blimark","year":"2015","journal-title":"Haematologica"},{"issue":"10068","key":"2019111903331569600_B52","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"key":"2019111903331569600_B53","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3389\/fimmu.2014.00257","article-title":"Immune defects in the risk of infection and response to vaccination in monoclonal gammopathy of undetermined significance and multiple myeloma","volume":"5","author":"Tete","year":"2014","journal-title":"Front Immunol"},{"issue":"1","key":"2019111903331569600_B54","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/bjh.13532","article-title":"Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy","volume":"171","author":"Teh","year":"2015","journal-title":"Br J Haematol"},{"issue":"11","key":"2019111903331569600_B55","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1586\/14787210.2015.1083858","article-title":"Prevention of viral infections in patients with multiple myeloma: the role of antiviral prophylaxis and immunization","volume":"13","author":"Teh","year":"2015","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"6","key":"2019111903331569600_B56","doi-asserted-by":"crossref","first-page":"980","DOI":"10.3324\/haematol.2012.075051","article-title":"Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials","volume":"98","author":"Bringhen","year":"2013","journal-title":"Haematologica"},{"issue":"2","key":"2019111903331569600_B57","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1365-2567.2007.02761.x","article-title":"Proteasome inhibition suppresses essential immune functions of human CD4+ T cells","volume":"124","author":"Berges","year":"2008","journal-title":"Immunology"},{"key":"2019111903331569600_B58","first-page":"CD004386","article-title":"Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy","volume":"1","author":"Gafter-Gvili","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"2019111903331569600_B59","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S0002-9343(95)00043-7","article-title":"Prophylactic antibiotics for the prevention of early infection in multiple myeloma","volume":"100","author":"Oken","year":"1996","journal-title":"Am J Med"},{"issue":"12","key":"2019111903331569600_B60","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1038\/leu.2012.124","article-title":"Oral antibiotic prophylaxis of early infection in multiple myeloma: a URCC\/ECOG randomized phase III study","volume":"26","author":"Vesole","year":"2012","journal-title":"Leukemia"},{"issue":"8905","key":"2019111903331569600_B61","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0140-6736(94)90180-5","article-title":"Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma","volume":"343","author":"Chapel","year":"1994","journal-title":"Lancet"},{"issue":"4","key":"2019111903331569600_B62","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/j.1365-2141.1995.tb08447.x","article-title":"Prophylaxis against infections with intravenous immunoglobulins in multiple myeloma","volume":"89","author":"Musto","year":"1995","journal-title":"Br J Haematol"},{"issue":"19","key":"2019111903331569600_B63","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma","volume":"366","author":"Palumbo","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111903331569600_B64","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","article-title":"2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours","volume":"47","author":"Aapro","year":"2011","journal-title":"Eur J Cancer"},{"issue":"10","key":"2019111903331569600_B65","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","article-title":"European Myeloma Network guidelines for the management of multiple myeloma-related complications","volume":"100","author":"Terpos","year":"2015","journal-title":"Haematologica"},{"issue":"4","key":"2019111903331569600_B66","doi-asserted-by":"crossref","first-page":"389","DOI":"10.6004\/jnccn.2016.0046","article-title":"NCCN guidelines insights: multiple myeloma, version 3.2016","volume":"14","author":"Anderson","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"key":"2019111903331569600_B67","unstructured":"CDC Centers for Disease Control and Prevention. https:\/\/www.cdc.gov\/pneumococcal\/vaccination.html. Accessed november 9, 2016."},{"issue":"9","key":"2019111903331569600_B68","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.clml.2016.06.006","article-title":"Vaccination in multiple myeloma: review of current literature","volume":"16","author":"Alemu","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"2019111903331569600_B69","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.3324\/haematol.2014.116772","article-title":"Efficacy of single versus boost vaccination against influenza virus in patients with multiple myeloma","volume":"100","author":"Hahn","year":"2015","journal-title":"Haematologica"},{"key":"2019111903331569600_B70","unstructured":"VZV vaccine for hematopoietic stem cell transplantation. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02329457?term=herpes+zoster&cond=stem+cell+transplantation&intr=vaccination&ran. Accessed November 9, 2016"},{"issue":"11","key":"2019111903331569600_B71","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"issue":"29","key":"2019111903331569600_B72","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1200\/JCO.2007.14.9641","article-title":"Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study","volume":"26","author":"Chanan-Khan","year":"2008","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111903331569600_B73","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.clml.2013.03.006","article-title":"Risk of rash associated with lenalidomide in cancer patients: a systematic review of the literature and meta-analysis","volume":"13","author":"Nardone","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"2019111903331569600_B74","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.aller.2013.07.005","article-title":"Cutaneous adverse reactions to lenalidomide","volume":"43","author":"Imbesi","year":"2015","journal-title":"Allergol Immunopathol (Madr)"},{"issue":"suppl","key":"2019111903331569600_B75","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1016\/j.clml.2015.02.008","article-title":"Practical management of lenalidomide-related rash","volume":"15","author":"Tinsley","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"2019111903331569600_B76","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.3109\/10428194.2016.1151507","article-title":"Outcomes and management of lenalidomide-associated rash in patients with multiple myeloma","volume":"57","author":"Barley","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2019111903331569600_B77","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/bjh.12925","article-title":"Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma","volume":"167","author":"Lee","year":"2014","journal-title":"Br J Haematol"},{"issue":"2","key":"2019111903331569600_B78","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"issue":"8","key":"2019111903331569600_B79","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1200\/JCO.2010.31.6844","article-title":"Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial","volume":"29","author":"Palumbo","year":"2011","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111903331569600_B80","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1038\/sj.leu.2403533","article-title":"Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy","volume":"18","author":"Minnema","year":"2004","journal-title":"Leukemia"},{"issue":"22","key":"2019111903331569600_B81","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.877.877","article-title":"Direct oral anticoagulants in patients with cancer [abstract]","volume":"128","author":"Shah","year":"2016","journal-title":"Blood"},{"issue":"5","key":"2019111903331569600_B82","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1093\/annonc\/mdt001","article-title":"Diagnosis and management of gastrointestinal complications in adult cancer patients: evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)","volume":"24","author":"Vehreschild","year":"2013","journal-title":"Ann Oncol"},{"issue":"15","key":"2019111903331569600_B83","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1182\/blood-2014-06-583302","article-title":"Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment","volume":"124","author":"Pawlyn","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2019111903331569600_B84","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/annonc\/mdw606","article-title":"Second primary malignancies in multiple myeloma: an overview and IMWG consensus","volume":"28","author":"Musto","year":"2017","journal-title":"Ann Oncol"},{"key":"2019111903331569600_B85","unstructured":"European Medicines Agency. Daratumumab Summary of Product Characteristics. Vol. 2016. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004077\/WC500207296.pdf:SPC daratumumab. Accessed December 10, 2016."},{"issue":"22","key":"2019111903331569600_B86","article-title":"Use of montelukast to reduce infusion reactions in an early access treatment protocol of daratumumab in united states patients with relapsed or refractory multiple myeloma [abstract]","volume":"128","author":"Chari","year":"2016","journal-title":"Blood"},{"issue":"22","key":"2019111903331569600_B87","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.1149.1149","article-title":"Open-label, multicenter, dose escalation phase 1b study to assess the subcutaneous delivery of daratumumab in patients (pts) with relapsed or refractory multiple myeloma (PAVO) [abstract]","volume":"128","author":"Usmani","year":"2016","journal-title":"Blood"},{"key":"2019111903331569600_B88","article-title":"Phase 1\/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma. Blood. 2016;blood-2016-07-729236 [published online ahead of print September 19, 2016]","author":"Nijhof"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/17\/2359\/1399822\/blood725705.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/17\/2359\/1399822\/blood725705.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,3]],"date-time":"2020-10-03T16:06:59Z","timestamp":1601741219000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/129\/17\/2359\/35945\/How-I-manage-the-toxicities-of-myeloma-drugs"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,27]]},"references-count":88,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2017,4,27]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2017-01-725705","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,27]]}}}